Identifying potential biomarkers in the hippocampus of chronic fatigue syndrome rats treated with moxibustion at Zusanli (ST36): a proteomics study. — CFSMEATLAS
E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedMachine draft
Standard · 3 min
Identifying potential biomarkers in the hippocampus of chronic fatigue syndrome rats treated with moxibustion at Zusanli (ST36): a proteomics study.
Chuwen, Feng, Chaoran, L I, Yan, Yang et al. · Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025 · DOI
Quick Summary
This study tested whether moxibustion—a traditional Chinese medicine technique involving gentle heat applied to a specific acupuncture point on the leg—could help rats with chronic fatigue syndrome. Researchers found that moxibustion improved the rats' activity levels, memory, and reduced damage to a brain region involved in learning and emotion. The treatment appeared to work by restoring balance to specific proteins in the brain that were abnormal in the fatigued rats.
Why It Matters
ME/CFS patients experience cognitive dysfunction and memory problems linked to hippocampal dysfunction; this study identifies specific protein abnormalities in a fatigue model that are reversible with treatment. If validated in humans, the 16 biomarkers could provide diagnostic tools and reveal treatment targets for cognitive symptoms in ME/CFS. Understanding multiple protein pathways involved in fatigue may help develop both traditional and conventional therapeutic approaches.
Observed Findings
Moxibustion treatment significantly reduced symptom scores and improved performance on behavioral tests (Open Field Test, treadmill endurance, Morris Water Maze) compared to untreated CFS-model rats.
Proteomic analysis identified 72 differentially expressed proteins in CFS-model rats versus healthy controls, with 31 increased and 41 decreased.
Moxibustion treatment reversed 14 out of 16 identified biomarker proteins toward normal levels, primarily involving synaptic plasticity, ribosomal function, neurotransmitter secretion, and mitochondrial proteins.
Hippocampal pathological damage and synaptic structural abnormalities observed on electron microscopy were partially repaired by moxibustion treatment.
Inferred Conclusions
Moxibustion at ST36 produces measurable improvements in fatigue-related behaviors and hippocampal protein composition in a stress-induced CFS rat model.
The therapeutic mechanism of moxibustion operates through multiple protein targets and biological pathways, particularly those regulating synaptic function, energy metabolism, and neuronal repair.
The 16 identified biomarkers may represent potential diagnostic and prognostic indicators for hippocampal dysfunction in CFS and targets for future therapeutic development.
Remaining Questions
Do these 16 hippocampal protein biomarkers correlate with hippocampal dysfunction and cognitive symptoms in human ME/CFS patients?
What This Study Does Not Prove
This study does not prove that moxibustion will be effective in human ME/CFS patients, as rat stress-induced fatigue may differ substantially from the complex pathophysiology of human disease. The protein changes identified are correlational and do not definitively establish cause-and-effect mechanisms in human hippocampal dysfunction. Animal model findings frequently fail to translate to clinical benefit in humans, requiring rigorous clinical trials before therapeutic claims can be made.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
What is the dose-response relationship and optimal timing for moxibustion treatment in this model, and how does it compare to other interventions?
Which of the identified proteins are causally responsible for hippocampal damage in CFS, versus secondarily altered as a consequence of stress exposure?
Can moxibustion treatment produce sustained long-term improvement in CFS rats, and does this model adequately represent human ME/CFS pathophysiology?